314 related articles for article (PubMed ID: 9438022)
21. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
Katakura S; Nagahara T; Hara T; Iwamoto M
Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
Koshio H; Hirayama F; Ishihara T; Shiraki R; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Kaku S; Katayama N; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2005 Feb; 13(4):1305-23. PubMed ID: 15670939
[TBL] [Abstract][Full Text] [Related]
23. Stereoselective synthesis and biological evaluation of 3,4-diaminocyclohexanecarboxylic acid derivatives as factor Xa inhibitors.
Nagata T; Nagamochi M; Kobayashi S; Komoriya S; Yoshino T; Kanno H
Bioorg Med Chem Lett; 2008 Aug; 18(16):4587-92. PubMed ID: 18675545
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units.
Haginoya N; Kobayashi S; Komoriya S; Yoshino T; Nagata T; Hirokawa Y; Nagahara T
Bioorg Med Chem; 2004 Nov; 12(21):5579-86. PubMed ID: 15465335
[TBL] [Abstract][Full Text] [Related]
25. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
[TBL] [Abstract][Full Text] [Related]
26. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
27. Design of benzamidine-type inhibitors of factor Xa.
Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
[TBL] [Abstract][Full Text] [Related]
28. Approaches to selective peptidic inhibitors of factor Xa.
Bromfield KM; Quinsey NS; Duggan PJ; Pike RN
Chem Biol Drug Des; 2006 Jul; 68(1):11-9. PubMed ID: 16923021
[TBL] [Abstract][Full Text] [Related]
29. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
30. The extended interactions and Gla domain of blood coagulation factor Xa.
Wang SX; Hur E; Sousa CA; Brinen L; Slivka EJ; Fletterick RJ
Biochemistry; 2003 Jul; 42(26):7959-66. PubMed ID: 12834348
[TBL] [Abstract][Full Text] [Related]
31. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P
J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508
[TBL] [Abstract][Full Text] [Related]
32. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
[TBL] [Abstract][Full Text] [Related]
33. Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa.
Lopopolo G; Fiorella F; de Candia M; Nicolotti O; Martel S; Carrupt PA; Altomare C
Eur J Pharm Sci; 2011 Feb; 42(3):180-91. PubMed ID: 21112391
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
[TBL] [Abstract][Full Text] [Related]
35. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
Qiao JX; Cheney DL; Alexander RS; Smallwood AM; King SR; He K; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4118-23. PubMed ID: 18550370
[TBL] [Abstract][Full Text] [Related]
36. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry.
Ostrem JA; al-Obeidi F; Safar P; Safarova A; Stringer SK; Patek M; Cross MT; Spoonamore J; LoCascio JC; Kasireddy P; Thorpe DS; Sepetov N; Lebl M; Wildgoose P; Strop P
Biochemistry; 1998 Jan; 37(4):1053-9. PubMed ID: 9454596
[TBL] [Abstract][Full Text] [Related]
38. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
[TBL] [Abstract][Full Text] [Related]
40. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies.
Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L
Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
